

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 86TH LEGISLATIVE REGULAR SESSION

April 8, 2019

TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services

FROM: John McGeady, Assistant Director Sarah Keyton, Assistant Director
Legislative Budget Board

IN RE: **SB1765** by Bettencourt (Relating to the administration and oversight of investigational adult stem cell treatments administered to certain patients.), **As Introduced**

No significant fiscal implication to the State is anticipated.

The bill would require that institutional review boards that oversee stem cell treatments either be accredited by the Association for the Accreditation of Human Research Protection programs, be registered by the United States Department of Health and Human Services, or be accredited by another national accreditation organization acceptable to the Department of State Health Services (DSHS). The bill would also prohibit a government entity from considering a drug adulterated or misbranded solely on the basis of the drug not being approved by United States Food and Drug Administration

DSHS, the Health and Human Services Commission and the Texas Medical Board indicate that the provisions of the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 503 Texas Medical Board, 529 Health and Human Services Commission,
537 State Health Services, Department of

LBB Staff: WP, AKi, JQ, BH